Navigation Links
Joseph Loscalzo, M.D., PhD. to Join N30 Pharma Board and Chair Scientific Advisory Board
Date:3/23/2009

BOULDER, Colo., March 23 /PRNewswire/ -- N30 Pharma (N30) today announced that Joseph Loscalzo, M.D., PhD., has joined the Board of Directors of the Company.

Dr. Loscalzo currently serves as Hersey Professor of the Theory and Practice of Medicine at Harvard, Physician-in-Chief at Brigham and Women's Hospital, Editor-in-Chief of Circulation, and has recently joined the senior editorial Board of Harrison's Principles of Internal Medicine. Dr. Loscalzo has longstanding research interests in cardiovascular medicine, nitric oxide and redox biology with over 500 scientific publications and authoring or editing of 24 books.

"I am pleased to join the Board of N30 at an exciting time for the company. N30 is developing compounds of substantial potential importance that offer a unique means for modulating endogenous NO in the cardiovascular and pulmonary systems, and I look forward to helping the Board in managing the future of the Company," Dr. Loscalzo commented.

Dr. Loscalzo will also Chair the company's Scientific Advisory Board. The N30 SAB will provide the company with world-class thinking on the key biological, biochemical, translational, and clinical issues associated with developing important new classes of therapeutics in cardiopulmonary medicine.

Dr. Charles Scoggin, CEO of N30, commented on the expansion of the Board. "We are thrilled that a world-class clinical and scientific mind like Dr. Loscalzo shares our excitement over the great clinical potential in N30 Pharma, and we will look forward to working closely with him as we move the company forward."

About N30 Pharma

N30 Pharma is a cardiopulmonary medicine company focused on the modulation of endogenous Nitric Oxide bioavailability using targeted novel small molecule drugs. The company is headquartered in Boulder, Colorado and New York City, NY.


'/>"/>
SOURCE N30 Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. PAREXEL Appoints Josephine Hoppe to Chief Information Officer
2. St. Josephs Hospital and Medical Center to Utilize Clinical InfoNET System for Physicians
3. Board of Directors of Milestone Scientific Names Joseph DAgostino Chief Financial Officer
4. St. Josephs Hospital and InNexus Biotechnology Enter Collaborative Partnership
5. WuXi AppTec Appoints Garry Takle, Ph.D. as VP of Operations and Joseph Hughes, Ph.D. as VP of Testing Services for Philadelphia Facility
6. Spherics, Inc. Assigns Assets to Joseph F. Finn, Jr., C.P.A.
7. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
8. Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
9. Dr. Joseph L. Corriveau Appointed Director of Research and Technology
10. SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors
11. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... 03, 2016 , ... Flagship Biosciences, the leader in ... Board of Directors. Dr. Gillett recently retired from Charles River Laboratories (CRL), where, ... Scientific Officer. A board-certified veterinary pathologist, Dr. Gillett joined Charles River in 1999 ...
(Date:5/3/2016)... 2016  Dr. Thomas P. McHugh , an ... The Woodlands, Texas , now offers SculpSure, the ... fat cells in just 25-minutes, leaving a slimmer figure ... of Americans report feeling bothered by excess weight and ... are a growing industry. This innovative new approach to ...
(Date:5/2/2016)... , ... May 02, 2016 , ... ... its clients in mind, the fresh look and added functionality give the agricultural ... years have seen a dynamic shift in agriculture – from precision farming via ...
(Date:4/29/2016)... ... 2016 , ... Proove Biosciences, Inc ., the commercial ... of the Proove Health Foundation . The Foundation is a non-profit organization ... of personalized medicine for tackling the nation’s most-pressing healthcare epidemics. As part of ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):